CGTBioSenic halts ALLOB developmentLatest NewsBioSenic SA has suspended its Phase II proof-of-concept trial on fracture healing with its allogeneic cell therapy ALLOB. Read more 19 June 2023 https://european-biotechnology.com/wp-content/uploads/2024/04/Bone_Therapeutics.jpeg 853 1280 Thomas Gabrielczyk /wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.png Thomas Gabrielczyk2023-06-19 22:14:002024-07-10 06:20:56BioSenic halts ALLOB development